Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience

Diabetes Research and Clinical Practice · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles